CenterBook Partners LP decreased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 9.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,635 shares of the biotechnology company's stock after selling 979 shares during the quarter. CenterBook Partners LP's holdings in Axon Enterprise were worth $5,068,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock worth $4,540,005,000 after buying an additional 185,571 shares in the last quarter. Geode Capital Management LLC boosted its position in Axon Enterprise by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock valued at $1,095,542,000 after purchasing an additional 65,097 shares in the last quarter. Capital World Investors boosted its position in Axon Enterprise by 86.4% during the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Alliancebernstein L.P. boosted its position in Axon Enterprise by 273.8% during the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its position in Axon Enterprise by 29.8% during the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock valued at $487,977,000 after purchasing an additional 212,931 shares in the last quarter. Institutional investors own 79.08% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the company an "overweight" rating in a research report on Friday, July 11th. Needham & Company LLC raised their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wolfe Research assumed coverage on Axon Enterprise in a research report on Monday, July 7th. They set an "outperform" rating on the stock. Bank of America raised their price objective on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. Finally, The Goldman Sachs Group raised their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $734.62.
Get Our Latest Stock Report on AXON
Insider Activity at Axon Enterprise
In related news, Director Michael Garnreiter sold 5,913 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the completion of the transaction, the director directly owned 17,740 shares in the company, valued at approximately $13,482,400. This trade represents a 25.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CRO Cameron Brooks sold 3,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the sale, the executive owned 19,447 shares of the company's stock, valued at $14,405,559.72. This trade represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock valued at $30,500,428 in the last 90 days. 4.40% of the stock is currently owned by corporate insiders.
Axon Enterprise Stock Performance
Shares of NASDAQ:AXON traded up $3.09 during trading on Thursday, hitting $745.86. The stock had a trading volume of 341,015 shares, compared to its average volume of 701,907. Axon Enterprise, Inc has a 12-month low of $279.02 and a 12-month high of $830.21. The stock has a market capitalization of $58.07 billion, a price-to-earnings ratio of 180.16, a price-to-earnings-growth ratio of 85.86 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The stock has a 50-day simple moving average of $760.96 and a two-hundred day simple moving average of $643.52.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. During the same period last year, the business posted $1.15 earnings per share. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. On average, equities research analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.
About Axon Enterprise
(
Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
